WAVE LIFE SCIENCES LTD. (WVE) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.63B; Additional Paid in CapitalUSD $248.16M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-172.00K; Retained Earnings (Accumulated Deficit)USD $-1.42B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.63B; Additional Paid in CapitalUSD $237.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-254.00K; Retained Earnings (Accumulated Deficit)USD $-1.35B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.62B; Additional Paid in CapitalUSD $228.37M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-250.00K; Retained Earnings (Accumulated Deficit)USD $-1.33B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.22B; Additional Paid in CapitalUSD $174.07M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-190.00K; Retained Earnings (Accumulated Deficit)USD $-1.27B.
WAVE LIFE SCIENCES LTD. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Preferred Stock, Value, Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.63B | $248.16M | $-172.00K | $-1.42B | $453.52M | (m) | 3 month · $0.00 6 month · $0.00 | (m) |
| 2026-03-31 | $1.63B | $237.43M | $-254.00K | $-1.35B | $511.73M | (m) | (m) | (m) |
| 2025-12-31 | $1.62B | $228.37M | $-250.00K | $-1.33B | $518.36M | 12 month · $46.94M | (m) | (m) |
| 2025-09-30 | $1.22B | $174.07M | $-190.00K | $-1.27B | $124.55M | (m) | (m) | (m) |
| 2025-06-30 | $1.19B | $167.60M | $-161.00K | $-1.22B | $139.27M | (m) | (m) | (m) |
| 2025-03-31 | $1.18B | $161.41M | $-204.00K | $-1.17B | $171.80M | (m) | (m) | (m) |
| 2024-12-31 | $1.18B | $156.45M | $-262.00K | $-1.12B | $209.51M | 12 month · $14.08M | (m) | (m) |
| 2024-09-30 | $1.14B | $153.20M | $-159.00K | $-1.15B | $141.64M | (m) | (m) | (m) |
| 2024-06-30 | $950.53M | $135.60M | $-279.00K | $-1.09B | $-3.48M | (m) | (m) | (m) |
| 2024-03-31 | $949.88M | $132.12M | $-198.00K | $-1.06B | $25.39M | (m) | (m) | (m) |
| 2023-12-31 | $935.37M | $129.24M | $-124.00K | $-1.02B | $39.63M | (m) | (m) | (m) |
| 2023-09-30 | $841.40M | $126.89M | $-182.00K | $-1.01B | $-40.49M | (m) | (m) | (m) |
| 2023-06-30 | $839.67M | $124.60M | $-150.00K | $-1.02B | $-51.72M | (m) | (m) | (m) |
| 2023-03-31 | $837.89M | $122.19M | $-50.00K | $-994.74M | $-34.71M | (m) | (m) | (m) |
| 2022-12-31 | $802.83M | $119.44M | $-29.00K | $-967.34M | $-45.09M | 12 month · $14.27M | (m) | (m) |
| 2022-09-30 | $802.70M | $116.53M | $-123.00K | $-923.63M | $-4.52M | (m) | (m) | (m) |
| 2022-06-30 | $802.45M | $113.17M | $-47.00K | $-884.62M | $30.95M | 3 month · $14.27M | (m) | (m) |
| 2022-03-31 | $751.23M | $91.95M | $95.00K | $-843.33M | $-53.00K | (m) | (m) | (m) |
| 2021-12-31 | $749.85M | $87.98M | $181.00K | $-805.51M | $32.50M | (m) | (m) | (m) |
| 2021-09-30 | $716.12M | $84.25M | $258.00K | $-770.73M | $29.90M | (m) | (m) | (m) |
| 2021-06-30 | $707.71M | $78.36M | $269.00K | $-764.50M | $21.84M | (m) | (m) | (m) |
| 2021-03-31 | $702.65M | $75.64M | $269.00K | $-725.73M | $52.82M | (m) | (m) | (m) |
| 2020-12-31 | $694.09M | $71.57M | $389.00K | $-683.27M | $82.78M | (m) | (m) | (m) |
| 2020-09-30 | $694.07M | $68.35M | $301.00K | $-654.48M | $108.24M | (m) | (m) | (m) |
| 2020-06-30 | $551.54M | $65.07M | $278.00K | $-621.38M | $-4.49M | (m) | (m) | (m) |
| 2020-03-31 | $540.16M | $61.28M | $273.00K | $-580.85M | $20.86M | (m) | (m) | (m) |
| 2019-12-31 | $539.55M | $57.28M | $267.00K | $-533.36M | $63.73M | (m) | (m) | (m) |
| 2019-09-30 | $538.79M | $52.29M | $282.00K | $-476.59M | $114.77M | (m) | (m) | (m) |
| 2019-06-30 | $538.54M | $47.27M | $280.00K | $-425.86M | $160.22M | (m) | (m) | (m) |
| 2019-03-31 | $538.41M | $42.11M | $250.00K | $-383.92M | $196.86M | (m) | (m) | (m) |
| 2018-12-31 | $375.15M | $37.77M | $153.00K | $-339.72M | $73.35M | (m) | (m) | (m) |
| 2018-09-30 | $374.50M | $33.76M | $181.00K | $-301.83M | $106.61M | (m) | (m) | (m) |
| 2018-06-30 | $373.15M | $30.15M | $201.00K | $-264.20M | $139.30M | (m) | (m) | (m) |
| 2018-03-31 | $311.59M | $26.60M | $165.00K | $-228.31M | $110.05M | (m) | (m) | (m) |
| 2017-12-31 | $310.04M | $22.17M | $116.00K | $-192.72M | $139.61M | (m) | (m) | (m) |
| 2017-09-30 | $309.43M | $19.00M | $-272.00K | $-162.30M | $165.86M | (m) | (m) | (m) |
| 2017-06-30 | $309.36M | $16.00M | $-273.00K | $-136.17M | $188.91M | (m) | (m) | (m) |
| 2017-03-31 | $215.81M | $13.03M | $-276.00K | $-111.47M | $117.09M | (m) | (m) | (m) |
| 2016-12-31 | $215.60M | $10.03M | $-291.00K | $-90.48M | $134.60M | (m) | (m) | (m) |
| 2016-09-30 | $215.50M | $7.57M | $84.00K | $-72.02M | $151.13M | (m) | (m) | (m) |
| 2016-06-30 | $215.37M | $5.32M | $76.00K | $-54.49M | $166.28M | (m) | (m) | (m) |
| 2016-03-31 | $185.34M | $4.05M | $52.00K | $-42.92M | $146.52M | (m) | (m) | (m) |
| 2015-12-31 | $185.34M | $3.18M | $41.00K | $-35.08M | $153.49M | (m) | (m) | (m) |
| 2015-09-30 | $22.45M | $2.37M | $43.00K | $-27.98M | $-3.12M | (m) | (m) | (m) |
| 2014-12-31 | $9.97M | (m) | $56.00K | $-15.88M | $2.03M | (m) | (m) | $7.87M |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-7.76M | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-4.58M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |